


ROR γ t inverse agonist 14

Cat. No.:	HY-132195
CAS No.:	2672496-70-5
Molecular Formula:	C ₂₆ H ₂₆ F ₈ N ₂ O ₆ S ₂
Molecular Weight:	678.61
Target:	ROR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ROR γ t inverse agonist 14 (8e) is a potent, orally active and selective ROR γ t inverse agonist (EC ₅₀ of 2.5 nM) with anti-inflammatory activity. ROR γ t inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis ^[1] .								
In Vivo	<p>RORγt inverse agonist 14 (8e) exhibits t_{1/2} of 11 h by iv injection of 1 mg/kg. RORγt inverse agonist 14 (8e) exhibits t_{max} of 2 h, %F of 101 by oral administration of 4 mg/kg in mouse^[1].</p> <p>RORγt inverse agonist 14 (8e, 5-20 mg/kg) provides essentially the same arthritic score reduction as a murine equivalent of the marketed TNF decoy receptor etanercept^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mouse model of psoriasis: acanthosis induced by IL-23^[1].</td> </tr> <tr> <td>Dosage:</td> <td>5, 10, 20 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Orally twice daily.</td> </tr> <tr> <td>Result:</td> <td>A dose-dependent reduction in ear thickening was observed.</td> </tr> </table>	Animal Model:	Mouse model of psoriasis: acanthosis induced by IL-23 ^[1] .	Dosage:	5, 10, 20 mg/kg.	Administration:	Orally twice daily.	Result:	A dose-dependent reduction in ear thickening was observed.
Animal Model:	Mouse model of psoriasis: acanthosis induced by IL-23 ^[1] .								
Dosage:	5, 10, 20 mg/kg.								
Administration:	Orally twice daily.								
Result:	A dose-dependent reduction in ear thickening was observed.								

REFERENCES

[1]. Qingjie Liu, et al. Azatricyclic Inverse Agonists of ROR γ t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis. ACS Med Chem Lett. 2021 Apr 30;12(5):827-835.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA